Ware RE - Search Results

1

Effects of hydroxyurea treatment for patients with hemoglobin SC disease.

Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE. Luchtman-Jones L, et al. Among authors: ware re. Am J Hematol. 2016 Feb;91(2):238-42. doi: 10.1002/ajh.24255. Am J Hematol. 2016. PMID: 26615793 Free article.

2

UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.

Heeney MM, Howard TA, Zimmerman SA, Ware RE. Heeney MM, et al. Among authors: ware re. J Lab Clin Med. 2003 Apr;141(4):279-82. doi: 10.1067/mlc.2003.28. J Lab Clin Med. 2003. PMID: 12677174 Clinical Trial.

3

Subclinical parvovirus B19 infection in children with sickle cell anemia.

Zimmerman SA, Davis JS, Schultz WH, Ware RE. Zimmerman SA, et al. Among authors: ware re. J Pediatr Hematol Oncol. 2003 May;25(5):387-9. doi: 10.1097/00043426-200305000-00007. J Pediatr Hematol Oncol. 2003. PMID: 12759625

4

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Zimmerman SA, et al. Among authors: ware re. Blood. 2004 Mar 15;103(6):2039-45. doi: 10.1182/blood-2003-07-2475. Epub 2003 Nov 20. Blood. 2004. PMID: 14630791 Free article. Clinical Trial.

5

Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease.

Jeng MR, Adams-Graves P, Howard TA, Whorton MR, Li CS, Ware RE. Jeng MR, et al. Among authors: ware re. Am J Hematol. 2003 Dec;74(4):243-8. doi: 10.1002/ajh.10426. Am J Hematol. 2003. PMID: 14635204 Free article.

6

Malignancy in patients with sickle cell disease.

Schultz WH, Ware RE. Schultz WH, et al. Among authors: ware re. Am J Hematol. 2003 Dec;74(4):249-53. doi: 10.1002/ajh.10427. Am J Hematol. 2003. PMID: 14635205 Free article.

7

Chemical and functional analysis of hydroxyurea oral solutions.

Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Heeney MM, et al. Among authors: ware re. J Pediatr Hematol Oncol. 2004 Mar;26(3):179-84. doi: 10.1097/00043426-200403000-00007. J Pediatr Hematol Oncol. 2004. PMID: 15125610

8

Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.

Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH. Ware RE, et al. J Pediatr. 2004 Sep;145(3):346-52. doi: 10.1016/j.jpeds.2004.04.058. J Pediatr. 2004. PMID: 15343189

9

Enalapril and hydroxyurea therapy for children with sickle nephropathy.

Fitzhugh CD, Wigfall DR, Ware RE. Fitzhugh CD, et al. Among authors: ware re. Pediatr Blood Cancer. 2005 Dec;45(7):982-5. doi: 10.1002/pbc.20296. Pediatr Blood Cancer. 2005. PMID: 15704213

10

Pelger-Huët anomaly in a child with 1q42.3-44 deletion.

Kalfa TA, Zimmerman SA, Goodman BK, McDonald MT, Ware RE. Kalfa TA, et al. Among authors: ware re. Pediatr Blood Cancer. 2006 May 1;46(5):645-8. doi: 10.1002/pbc.20504. Pediatr Blood Cancer. 2006. PMID: 16007606

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

378 results

Search Page

Filters